Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus PIRMELLA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus PIRMELLA 7 7 7.
ENOVID-E vs PIRMELLA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal: 70% unchanged; fecal: 30% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive